Quantitation of DNA topoisomerase IIα and β in human leukaemia cells by immunoblotting

Leukemia

Volumn 14, Issue 11, 2000, Pages 1997-2005

  Padget, K ^a   Pearson, A D J ^b   Austin, C A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

DNA topoisomerase II; Etoposide; Leukaemia

Indexed keywords

DEOXYRIBONUCLEASE I; DNA TOPOISOMERASE (ATP HYDROLYSING); DODECYL SULFATE SODIUM; RECOMBINANT ENZYME; RIBONUCLEASE A; SODIUM CHLORIDE;

ACCURACY; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME ASSAY; EXTRACTION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHOBLAST; MALE; METHODOLOGY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SALINITY; SOLUBILIZATION; WESTERN BLOTTING;

EID: 0033763363     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401928     Document Type: Article

References (36)

1. DNA topoisomerases
2. DNA topoisomerase II mutant of Saccharomyces cerevisiae topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication
3. Swiveling and decatenation of replicating simian virus 40 genomes in vivo
4. Chromosome assembly in vitro: Topoisomerase II is required for condensation
5. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
6. Etoposide targets topoisomerase IIα and IIβ in leukaemia cells: Isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique
7. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumour cells
8. DNA topoisomerases: Essential enzymes and lethal targets
9. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line
10. Genetic transfer of non-P-glycoprotein-mediated multi-drug resistance (MDR) in somatic cell fusion: Dissection of a compound MDR phenotype
11. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukaemia cell lines
12. Role of topoisomerase IIβ in the resistance of 9-OH-elliptincine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors
13. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase II alpha in yeast
14. Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIβ
15. Identification of an E1A-inducible cellular factor that interacts with regulatory sequences within the adenovirus E4 promoter
16. Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16
17. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukaemic cells selected for resistance to VM-26
18. Nuclear distribution of human DNA topoisomerase IIβ: A nuclear targeting signal resides in the 116-residue C-terminal tail
19. Physiological regulation of eukaryotic topoisomerase II
20. Inhibition of calf thymus type II DNA topoisomerase by poly (ADP)-ribosylation
21. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
22. Topoisomerase II levels during granulocytic maturation in vitro and in vivo
23. Topoisomerase IIα and β in human tumour cells grown in vitro and in vivo
24. Differences between normal and rastransformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II
25. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2beta construct allows the study of topoisomerase IIβ inhibitors in yeast
26. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: Analysis of cytotoxicity and cleavable complex formation
27. DNA topoisomerase IIα is the major chromosome protein recognised by the mitotic phosphoprotein antibody MPM-2
28. Expression of the 170-kDa and 180-kDa isoforms of DNA topoisomerase II in resting and proliferating lymphocytes
29. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase
30. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues
31. Topoisomerase II: A specific marker for cell proliferation
32. Cell cycle analysis in lymphoid neoplasia of childhood: Differences among immunologic subtypes and similarities in the proliferation of normal and leukaemic precursor B cells
33. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukaemia
34. Addition of etoposide to initial therapy of adult acute lymphoblastic leukaemia: A combined clinical and laboratory study
35. Etoposide-induced DNA strand breaks in relation to P-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL